Trump Administration Announces Projected Savings From Drug Pricing Agreements

The Trump administration is touting massive projected savings from its still-secret drug pricing deals, though outside experts say there is little way to independently verify the math. STAT reported the administration’s claims on May 7, 2026. The same day brought multiple other developments across biotech and drug regulation.

FDA leadership is facing fresh accusations of political interference in drug reviews. The agency will reconsider a treatment for rare cancer after its surprise rejection a few months ago. STAT reported that the FDA plans to revisit the rare cancer treatment.

The move follows the agency’s unexpected decision to reject the therapy several months earlier. A next-gen Duchenne drug from Entrada disappointed. STAT reported the trial results, which fell short of expectations for the therapy aimed at Duchenne muscular dystrophy.

1B. The acquisition, reported by STAT, gives Angelini a portfolio of treatments for rare diseases. Novo Nordisk’s less-bad news on its Wegovy pill boosted earnings and share price.

STAT reported that the Danish drugmaker’s update on the oral version of its popular weight-loss treatment exceeded some investor fears, driving gains in its stock and quarterly results. AI oncology startups are trying to make cancer care virtual. STAT described efforts by several companies to shift parts of oncology treatment into virtual formats using artificial intelligence tools.

The work, covered by STAT, explores previously uncharted regions of human proteins that could yield new therapeutic targets. Meghana Keshavan, a Biotech Correspondent who covers biotech and contributes to The Readout newsletter, wrote the article published on May 7, 2026.

The piece appears in STAT’s The Readout newsletter, which offers a morning rundown of the science, politics, and money driving biotech.

The Trump administration’s savings projections come without public details on the specific deals or the methodology used to calculate future reductions in drug spending. Outside experts highlighted the absence of transparent data that would allow independent confirmation of the touted savings figures.

Accusations of political interference at the FDA center on recent drug review decisions that some stakeholders view as influenced by external pressures rather than purely scientific evidence.

The agency’s decision to reopen review of the rare cancer treatment follows internal and external pushback after the initial surprise rejection. Entrada’s next-generation Duchenne drug had been viewed as a potential advance over existing therapies. Its disappointing results represent a setback for the company and for patients awaiting new options in a disease with limited treatments.

U.S. rare disease market. The deal includes Catalyst’s portfolio of approved therapies and ongoing development programs.

Novo Nordisk’s update on its Wegovy pill provided relief to investors concerned about competition in the weight-loss drug space. The company’s earnings and share price rose following the release of data that were not as negative as some analysts had anticipated. The virtual AI cancer clinic initiatives seek to reduce the need for in-person visits while maintaining quality of care.

Startups are deploying AI to assist with monitoring, treatment planning, and patient management in oncology. Research into the “dark proteome” focuses on thousands of protein variants that standard biological databases have largely overlooked. Scientists hope the emerging data will reveal new mechanisms of disease and opportunities for drug development.